HCV/HIV coinfection: SOF-based regimens effective pre- and post-LT

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Sofosbuvir (SOF; Sovaldi)-based regimens are safe and effective for HCV/HIV-coinfected patients who are liver transplant (LT) candidates or recipients.
  • When combined with an NS5A inhibitor, clearance rates topped 90%.

Why this matters

  • Pre-LT therapy should be considered for HIV-coinfected patients because of high wait-list mortality.

Study design

  • Multicenter Italian study of 48 HIV/HCV-coinfected patients receiving SOF-based therapy before (n=24) and after (n=24) LT for decompensated cirrhosis or hepatocellular carcinoma.
  • 69% were treatment-experienced; HCV-1 was most common (60%).
  • Primary endpoint was sustained virologic response at 12 wk posttherapy (SVR12).
  • Funding: None.

Key results

  • Suboptimal SOF + ribavirin (RBV) was used in 19 patients; the remainder received SOF/ledipasvir (Harvoni) o...